Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra

Trial Profile

Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra

Discontinued
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Rifabutin (Primary) ; Lopinavir/ritonavir
  • Indications HIV infections; Mycobacterium avium complex infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 13 Nov 2015 Status changed from recruiting to discontinued as per results published at The Journal of antimicrobial chemotherapy
    • 16 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top